english.prescrire.org > Spotlight > 100 most recent > In the March issue of Prescrire International: polatuzumab vedotin (Polivy°) and large B-cell lymphoma

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the March issue of Prescrire International: polatuzumab vedotin (Polivy°) and large B-cell lymphoma

FREE DOWNLOADPolatuzumab vedotin has been granted conditional European marketing authorisation for certain patients with relapsed or refractory diffuse large B-cell lymphoma. How do Prescrire's editors rate this option?
Full text available for free download.

  • Polatuzumab vedotin (Polivy°) as an adjunct to bendamustine + rituximab has been granted conditional European marketing authorisation for use in adults with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for haemopoietic stem cell transplantation.
     
  •  NOT ACCEPTABLE  A single randomised comparative trial with numerous methodological flaws evaluated the addition of polatuzumab vedotin to a drug combination which is relevant in this situation.

©Prescrire 1 March 2021

Source: "Polatuzumab vedotin (Polivy°) and large B-cell lymphoma" Prescrire International 2021; 30 (224): 65. Free.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


Prescrire's rating

Prescrire's rating
 NOT ACCEPTABLE 

Read more:

All the subjects in
Prescrire's Spotlight
Free >